Morepen Laboratories gains CDSCO approval for Resmetirom bioequivalence studies, positioning the company for global NASH ...

Morepen Laboratories has got clearance from Subject Expert Committee (SEC) of Central Drugs Standard Control Organization (CDSCO) to conduct Bioequivalence (BE) studies for Resmetirom 60 mg, 80 mg and ...

A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a ...

Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing efimosfermin alfa, a once-monthly FGF21 analogue for the treatment of metabolic dysfunction-associated steatohepatitis ...

The global primary sclerosing cholangitis (PSC) market is on an impressive growth trajectory, with forecasts estimating a market valuation of USD 314.26 million by 2033. This robust expansion is ...

Ignoring these can lead to inflammation, fatty liver disease, or even liver failure over time. Read on factors that can ...

A delayed reactive approach is putting millions at risk, especially because many serious conditions, like diabetes, ...